TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:TEVA • US8816242098

36.25 USD
+0.73 (+2.06%)
At close: Feb 3, 2026
36.4 USD
+0.15 (+0.41%)
After Hours: 2/3/2026, 8:04:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TEVA. TEVA was compared to 191 industry peers in the Pharmaceuticals industry. TEVA scores excellent on profitability, but there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on TEVA.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • TEVA had positive earnings in the past year.
  • TEVA had a positive operating cash flow in the past year.
  • In multiple years TEVA reported negative net income over the last 5 years.
  • TEVA had a positive operating cash flow in each of the past 5 years.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B -15B

1.2 Ratios

  • TEVA has a better Return On Assets (3.46%) than 83.25% of its industry peers.
  • TEVA's Return On Equity of 17.81% is amongst the best of the industry. TEVA outperforms 89.53% of its industry peers.
  • The Return On Invested Capital of TEVA (9.93%) is better than 89.53% of its industry peers.
  • TEVA had an Average Return On Invested Capital over the past 3 years of 9.79%. This is below the industry average of 12.83%.
  • The 3 year average ROIC (9.79%) for TEVA is below the current ROIC(9.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROIC 9.93%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)9.79%
ROIC(5y)8.89%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • With an excellent Profit Margin value of 8.16%, TEVA belongs to the best of the industry, outperforming 83.25% of the companies in the same industry.
  • With an excellent Operating Margin value of 19.87%, TEVA belongs to the best of the industry, outperforming 87.43% of the companies in the same industry.
  • In the last couple of years the Operating Margin of TEVA has remained more or less at the same level.
  • With a decent Gross Margin value of 52.89%, TEVA is doing good in the industry, outperforming 65.44% of the companies in the same industry.
  • TEVA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 19.87%
PM (TTM) 8.16%
GM 52.89%
OM growth 3Y-2.92%
OM growth 5Y0.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TEVA is still creating some value.
  • The number of shares outstanding for TEVA has been increased compared to 1 year ago.
  • TEVA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, TEVA has an improved debt to assets ratio.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • The Debt to FCF ratio of TEVA is 14.64, which is on the high side as it means it would take TEVA, 14.64 years of fcf income to pay off all of its debts.
  • TEVA's Debt to FCF ratio of 14.64 is fine compared to the rest of the industry. TEVA outperforms 76.96% of its industry peers.
  • A Debt/Equity ratio of 1.89 is on the high side and indicates that TEVA has dependencies on debt financing.
  • The Debt to Equity ratio of TEVA (1.89) is worse than 78.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF 14.64
Altman-Z N/A
ROIC/WACC1.22
WACC8.15%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • TEVA has a Current Ratio of 1.04. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.04, TEVA is doing worse than 83.77% of the companies in the same industry.
  • TEVA has a Quick Ratio of 1.04. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of TEVA (0.80) is worse than 81.15% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.8
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 17.27% over the past year.
  • TEVA shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.89% yearly.
  • TEVA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.32%.
  • Measured over the past years, TEVA shows a small growth in Revenue. The Revenue has been growing by 0.71% on average per year.
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%

3.2 Future

  • Based on estimates for the next years, TEVA will show a small growth in Earnings Per Share. The EPS will grow by 3.67% on average per year.
  • Based on estimates for the next years, TEVA will show a small growth in Revenue. The Revenue will grow by 1.00% on average per year.
EPS Next Y-4.58%
EPS Next 2Y3.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.34%
Revenue Next 2Y1%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.12, the valuation of TEVA can be described as correct.
  • 88.48% of the companies in the same industry are more expensive than TEVA, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of TEVA to the average of the S&P500 Index (28.18), we can say TEVA is valued rather cheaply.
  • TEVA is valuated correctly with a Price/Forward Earnings ratio of 12.72.
  • Based on the Price/Forward Earnings ratio, TEVA is valued cheaper than 85.34% of the companies in the same industry.
  • TEVA is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.51, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.12
Fwd PE 12.72
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 85.34% of the companies listed in the same industry.
  • TEVA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TEVA is cheaper than 80.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 36.22
EV/EBITDA 12.37
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

  • TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.67%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • TEVA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (2/3/2026, 8:04:00 PM)

After market: 36.4 +0.15 (+0.41%)

36.25

+0.73 (+2.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-28
Earnings (Next)05-05
Inst Owners14.54%
Inst Owner Change-0.7%
Ins Owners0.42%
Ins Owner Change-1.67%
Market Cap41.58B
Revenue(TTM)17.26B
Net Income(TTM)1.41B
Analysts82.86
Price Target0.11 (-99.7%)
Short Float %2.94%
Short Ratio3.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.53%
Min EPS beat(2)16.51%
Max EPS beat(2)38.54%
EPS beat(4)4
Avg EPS beat(4)16.39%
Min EPS beat(4)4.65%
Max EPS beat(4)38.54%
EPS beat(8)7
Avg EPS beat(8)8.31%
EPS beat(12)9
Avg EPS beat(12)5.55%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)2
Avg Revenue beat(2)3.32%
Min Revenue beat(2)0.9%
Max Revenue beat(2)5.75%
Revenue beat(4)2
Avg Revenue beat(4)-0.7%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)0.11%
Revenue beat(12)8
Avg Revenue beat(12)1.11%
Revenue beat(16)8
Avg Revenue beat(16)-0.59%
PT rev (1m)0.38%
PT rev (3m)102.69%
EPS NQ rev (1m)3.7%
EPS NQ rev (3m)7.9%
EPS NY rev (1m)1.21%
EPS NY rev (3m)2.6%
Revenue NQ rev (1m)0.96%
Revenue NQ rev (3m)2.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.1%
Valuation
Industry RankSector Rank
PE 12.12
Fwd PE 12.72
P/S 2.41
P/FCF 36.22
P/OCF 25.22
P/B 5.26
P/tB N/A
EV/EBITDA 12.37
EPS(TTM)2.99
EY8.25%
EPS(NY)2.85
Fwd EY7.86%
FCF(TTM)1
FCFY2.76%
OCF(TTM)1.44
OCFY3.97%
SpS15.04
BVpS6.9
TBVpS-10.35
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.54
Profitability
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROCE 12.57%
ROIC 9.93%
ROICexc 11.42%
ROICexgc 68.51%
OM 19.87%
PM (TTM) 8.16%
GM 52.89%
FCFM 6.65%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)9.79%
ROIC(5y)8.89%
ROICexc(3y)11.13%
ROICexc(5y)9.93%
ROICexgc(3y)65.11%
ROICexgc(5y)55.38%
ROCE(3y)12.4%
ROCE(5y)11.26%
ROICexgc growth 3Y16.18%
ROICexgc growth 5Y11.01%
ROICexc growth 3Y9.88%
ROICexc growth 5Y9.93%
OM growth 3Y-2.92%
OM growth 5Y0.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF 14.64
Debt/EBITDA 3.38
Cap/Depr 50%
Cap/Sales 2.9%
Interest Coverage 250
Cash Conversion 37.21%
Profit Quality 81.48%
Current Ratio 1.04
Quick Ratio 0.8
Altman-Z N/A
F-Score8
WACC8.15%
ROIC/WACC1.22
Cap/Depr(3y)47.55%
Cap/Depr(5y)45.36%
Cap/Sales(3y)3.08%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
EPS Next Y-4.58%
EPS Next 2Y3.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%
Revenue Next Year0.34%
Revenue Next 2Y1%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.19%
EBIT growth 3Y1.9%
EBIT growth 5Y1.25%
EBIT Next Year18.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.27%
FCF growth 3Y3.28%
FCF growth 5Y12.47%
OCF growth 1Y32.24%
OCF growth 3Y1.22%
OCF growth 5Y6.28%

TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ

What is the fundamental rating for TEVA stock?

ChartMill assigns a fundamental rating of 4 / 10 to TEVA.


What is the valuation status of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.


Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?

TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 7 / 10.


What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 12.12 and the Price/Book (PB) ratio is 5.26.


What is the earnings growth outlook for TEVA PHARMACEUTICAL-SP ADR?

The Earnings per Share (EPS) of TEVA PHARMACEUTICAL-SP ADR (TEVA) is expected to decline by -4.58% in the next year.